Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus CEFTRIAXONE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER versus CEFTRIAXONE IN PLASTIC CONTAINER.
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER vs CEFTRIAXONE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. It is resistant to many beta-lactamases.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 6-8 hours. Maximum 12 g/day.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
None Documented
None Documented
Terminal elimination half-life: 0.7-1.1 hours (normal renal function); prolonged to 5-13 hours in severe renal impairment (CrCl <10 mL/min)
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Renal: 85-90% unchanged via glomerular filtration and tubular secretion; biliary: <5%; fecal: <1%
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic